Emerging and High Growth Companies

AtomVie in its spinout and Series A Financing

AtomVie Global Radiopharma
Key Contact
David Jamieson

Partner, Emerging and High Growth Companies, Toronto

Team
Andrew Irwin

Associate, Emerging and High Growth Companies, Toronto

Jeremy Lin

Associate, Emerging and High Growth Companies, Toronto

Nathaniel Lipkus

Partner, Intellectual Property, Toronto

Kelly O’Ferrall

Partner, Employment and Labour, Ottawa

Simon Hodgett

Partner, Technology, Toronto

Matthew Ritchie

Partner, Real Estate, Toronto

Mike Jankowski

Associate, Technology, Toronto

 

On August 24, 2022, AtomVie Global Radiopharma Inc. announced it had completed its series A funding with Avego Management, LLC, an investment firm specializing in healthcare. With this funding, AtomVie plans to expand their production capability by building a new state-of-the-art facility.

AtomVie is a spinout from the Centre for Probe Development and Commercialization. They are a leading global CDMO (Contract Development and Manufacturing Organization) that develops, manufactures, and distributes radiopharmaceuticals.

Osler, Hoskin & Harcourt LLP advised AtomVie with a team consisting of David Jamieson, Andrew Irwin, Jeremy Lin, Darren Gill (Emerging and High Growth Companies), Nathaniel Lipkus (Intellectual Property), Kelly O’Ferrall (Employment and Labour), Simon Hodgett, Mike Jankowski (Technology), and Matthew Ritchie (Real Estate).

Value
-
Date Closed
August 24, 2022
Lead Office
Toronto
Key Contact
David Jamieson

Partner, Emerging and High Growth Companies, Toronto

Team
Andrew Irwin

Associate, Emerging and High Growth Companies, Toronto

Jeremy Lin

Associate, Emerging and High Growth Companies, Toronto

Nathaniel Lipkus

Partner, Intellectual Property, Toronto

Kelly O’Ferrall

Partner, Employment and Labour, Ottawa

Simon Hodgett

Partner, Technology, Toronto

Matthew Ritchie

Partner, Real Estate, Toronto

Mike Jankowski

Associate, Technology, Toronto